Proactive Investors - Run By Investors For Investors

Aphria's Colombian subsidiary Colcanna partners with Colombian Medical Federation

A new academic curriculum will offer Colombia’s doctors and medical professionals a source of information on medical cannabis
South America
Aphria produces and sells medical cannabis in Canada and internationally

Aphria Inc (TSX:APHA) (NYSE:APHA) announced Wednesday that its Colombian subsidiary, Colcanna SAS is partnering with the Federación Médica Colombiana, a national guild that oversees the ethics of the medical profession in Colombia, to develop an academic curriculum on the medicinal use of cannabis.

The new guidance will offer Colombia’s doctors and medical professionals a credible source of information on medical cannabis. The Federación Médica Colombiana (FMC) has nearly 2,000 affiliated doctors as well as more than 70,000 medical professionals who access the organization's materials for research and education.

READ: Aphria reports higher 1Q fiscal first quarter revenue and looks ahead to cannabis legalization in Canada

The medical cannabis curriculum developed by Colcanna and FMC will be made accessible on FMC’s online platform which offers courses on a range of subjects.

“Education in the medical community is critical for sustaining the advancement of medical cannabis in Colombia,” said Gabriel Meneses, vice-president for Latin America and the Caribbean with Aphria in a statement.

Headquartered in Leamington, Ontario, Aphria produces and sells medical cannabis in Canada and internationally.

Aphria shares were down slightly in pre-market trading in New York on Wednesday, slipping by 0.7% to hit $5.65.

Contact Ellen Kelleher at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full APH profile View Profile

Aphria Timeline

Related Articles

The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
medicinal cannabis concept
January 30 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use